Medicare Part D | Citizens Against Government Waste
The WasteWatcher: The Staff Blog of Citizens Against Government Waste

Medicare Part D

Senate Finance Committee Drug Pricing Changes - Market Driven or More Destructive Price Controls?

The healthcare policy community is anxiously waiting to see what kind of pharmaceutical pricing legislation Senate Finance Committee Chairman Chuck Grassley (R-Iowa) and Ranking Member Ron Wyden (D-Ore.) will produce for Medicare and Medicaid drug plans when Congress returns from the Independence Day break.  Will the shallow, but damaging, policy of instituting price controls be utilized or will enhanced competitive private-sector negotiations be allowed to take hold?  Because competition always leads to lower costs and more innovation, Citizens Against Government Waste (CAGW) hopes it is t

They’re Baaaaack – The Sequel

In their never-ending quest to run roughshod and exert control over the research-intensive biopharmaceutical industry, socialists in Congress have introduced various price-control bills.  For some reason they continue to think innovative drugs that cure cancer or other chronic diseases, such as hepatitis C, are whipped up in a back room with a 1970s-style “

Fix the BBA Allocation Flip and Medicare Cliff in Part D

Congress is back from its summer hiatus and there will be a flurry of activity the next few weeks.  With the elections just around the corner, there is a lot to get done before mid-October, when members will be returning home to campaign.  Citizens Against Government Waste (CAGW) hopes Congress will use this time to fix some of the harmful changes made to our healthcare system thanks to the Patient Protection and Affordable Care Act (ACA), or Obamacare.  Congress could start with repairing damage done to Medicare Part D that was further aggravated with a policy change implemented in the 201

Conservative Groups Oppose Medicare Part D Changes in the BBA

On March 8, Citizens Against Government Waste (CAGW), penned a blog which pointed out a harmful and major change to Medicare Part D that will cost pharmaceutical manufacturers far more than anticipated: $4.1 billion over 10 years, a 53 percent increase from the Congressional Budget Office’s (CBO) original score.  Some may think whacking pharmaceutical manufacturers with an additional, unexpected cost of $4.1 billion over ten years to the

President Trump's Drug Costs Proposals Coming Soon

The President has already made some good policy decisions and has offered other proposals that will help to lower drug costs.

The BBA, Medicare Part D, and a Cautionary Tale

When President Trump signed the Bipartisan Budget Act (BBA) for fiscal years 2018 and 2019 on February 9, 2018, Citizens Against Government Waste (CAGW) objected because of its prolific and irresponsible spending, calling the $300 billion (14 percent) increase over current levels “outrageous and unnecessary, as well as a complete abdication of fiscal discipline and accountability.”

Another Dumb Idea from Democrats on Drug Costs

Today, House Oversight and Government Reform Committee Ranking Member Elijah Cummings (D-Md.), Sen. Patrick Leahy (D-Vt.), Sen. Bernie Sanders (I-Vt.), Rep. Lloyd Doggett (D-Texas) and Rep. Peter Welch (D-Vt.), held a press conference to engage in their usual screed  against pharmaceutical companies and provide a “solution” to lower drug costs in Medicare Part D.  Rep.

Sign Up for Email Updates!Click Here!

View Archives

Posts by Author

Posts by Tag

Big Government (152) Obamacare (85) Congress (81) Healthcare (76) Waste (75) Budget (75) Uncategorized (56) Telecommunications (50) Internet (49) Debt (47) Technology (47) Deficit (44)